1. Peric A, Annaert W. Early etiology of Alzheimer's disease: tipping the balance toward autophagy or endosomal dysfunction? Acta Neuropathol. 2015; 129(3): 363-81. [DOI:10.1007/s00401-014-1379-7]

2. Dal Forno G, Palermo MT, Donohue JE, Karagiozis H, Zonderman AB, Kawas CH. Depressive symptoms, sex, and risk for Alzheimer's disease. Ann Neurol. 2005; 57(3): 381-7. [DOI:10.1002/ana.20405]

3. Risacher SL, Saykin AJ. Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol. 2013; 9: 621-48. [DOI:10.1146/annurev-clinpsy-050212-185535]

4. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014; 88(4): 640-51. [DOI:10.1016/j.bcp.2013.12.024]

5. Vinters HV. Emerging concepts in Alzheimer's disease. Annual Review of Pathology. Mechanisms of Disease. 2015; 10: 291-319. [DOI:10.1146/annurev-pathol-020712-163927]

6. Khachaturian ZS. Diagnosis of Alzheimer's disease. Archives of Neurology. 1985; 42(11): 1097-105. [DOI:10.1001/archneur.1985.04060100083029]

7. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001; 81(2): 741-66. [DOI:10.1152/physrev.2001.81.2.741]

8. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A. 2006; 103(49): 18727-32. [DOI:10.1073/pnas.0606298103]

9. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002; 298(5594): 789-91. [DOI:10.1126/science.1074069]

10. Rossor M, Fox N, Freeborough P, Harvey R. Clinical features of sporadic and familial Alzheimer's disease. Neurodegeneration. 1996; 5(4): 393-7. [DOI:10.1006/neur.1996.0052]

11. Dorostkar MM, Zou C, Blazquez-Llorca L, Herms J. Analyzing dendritic spine pathology in Alzheimer's disease: problems and opportunities. Acta Neuropathol. 2015; 130(1): 1-19. [DOI:10.1007/s00401-015-1449-5]

12. Manocha GD, Floden AM, Rausch K, Kulas JA, McGregor BA, Rojanathammanee L, et al. APP regulates microglial phenotype in a mouse model of Alzheimer's disease. J Neurosci. 2016; 36(32): 8471-86. [DOI:10.1523/JNEUROSCI.4654-15.2016]

13. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis. 2002; 9(1): 61-8. [DOI:10.1006/nbdi.2001.0460]

14. Cheon M, Dierssen M, Kim S, Lubec G. Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids. 2008; 35(2): 339-43. [DOI:10.1007/s00726-007-0618-9]

15. Association As. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016; 12(4): 459-509. [DOI:10.1016/j.jalz.2016.03.001]

16. Duce JA, Bush AI. Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Prog Neurobiol. 2010; 92(1): 1-18. [DOI:10.1016/j.pneurobio.2010.04.003]

17. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370(4): 322-33. [DOI:10.1056/NEJMoa1304839]

18. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016; 537(7618): 50-6. [DOI:10.1038/nature19323]

19. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002; 1(1): 13-20. [DOI:10.1151/spp021113]

20. Sutoo De, Akiyama K. Regulation of brain function by exercise. Neurobiol Dis. 2003; 13(1): 1-14. [DOI:10.1016/S0969-9961(03)00030-5]

21. Devi L, Ohno M. 7, 8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 2012; 37(2): 434-44. [DOI:10.1038/npp.2011.191]

22. Vassar R, Kandalepas PC. The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. Alzheimers Res Ther. 2011; 3(3): 20. doi: 10.1186/alzrt82. [DOI:10.1186/alzrt82]